ArticleInfection and immunity2003
Characterization of Brucella abortus O-polysaccharide and core lipopolysaccharide mutants and demonstration that a complete core is required for rough vaccines to be efficient against Brucella abortus and Brucella ovis in the mouse model.
Article in Infection and immunity, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 2 syntheses or guidelines pooled it, 109 citations in OpenAlex.
- Meta-Analysis and Advancement of Brucellosis Vaccinology.PloS one · 2016Pooled it
- Meta-analysis of variables affecting mouse protection efficacy of whole organism Brucella vaccines and vaccine candidates.BMC bioinformatics · 2013Pooled it
- A Meta-Analysis of the Protective Efficacy ofMicroorganisms · 2026Article
- Comprehensive genomic identification of essential genes required for Brucella melitensis intracellular survival during macrophage infection.Scientific reports · 2026Article
- Conjunctival administration of H38ΔwbkF rough vaccine as an effective strategy to protect against Brucella ovis infection while minimizing serological interference.Veterinary research · 2026Article
- Genomic and Immunoinformatics Insights Into a Bovine-Derived Brucella abortus S19 Field Strain: Adaptations Impacting Vaccine Efficacy.Veterinary medicine and science · 2025Article
- Development and evaluation of a novel lateral flow immunoassay for rapid diagnosis of brucellosis across different animal species.Scientific reports · 2025Article
- Brucellosis: Bacteriology, pathogenesis, epidemiology and role of the metallophores in virulence: a review.Frontiers in cellular and infection microbiology · 2025Review
- A review of three decades of use of the cattle brucellosis rough vaccine Brucella abortus RB51: myths and facts.BMC veterinary research · 2023Review
- TheAnnual review of microbiology · 2023Review
- A Brucella melitensis H38ΔwbkF rough mutant protects against Brucella ovis in rams.Veterinary research · 2022Article
- Article
- Immunization withVaccines · 2021Article
- Uncovering the Hidden Credentials ofMicrobiology and molecular biology reviews : MMBR · 2021Review
- Brucella abortus S19 GFP-tagged vaccine allows the serological identification of vaccinated cattle.PloS one · 2021Article
- When the Going Gets Rough: The Significance ofFrontiers in microbiology · 2021Review
- Genomic Analysis of Natural RoughInternational journal of molecular sciences · 2020Article
- Development of attenuated live vaccine candidates against swine brucellosis in a non-zoonotic B. suis biovar 2 background.Veterinary research · 2020Article
- The Three Flagellar Loci ofFrontiers in veterinary science · 2020Article
- NewIranian journal of biotechnology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brucella abortus rough lipopolysaccharide (LPS) mutants were obtained by transposon insertion into two wbk genes (wbkA [putative glycosyltransferase; formerly rfbU] and per [perosamine synthetase]), into manB (pmm [phosphomannomutase; formerly rfbK]), and into an unassigned gene. Consistent with gene-predicted roles, electrophoretic analysis, 2-keto-3-manno-D-octulosonate measurements, and immunoblots with monoclonal antibodies to O-polysaccharide, outer and inner core epitopes showed no O-polysaccharide expression and no LPS core defects in the wbk mutants. The rough LPS of manB mutant lacked the outer core epitope and the gene was designated manB(core) to distinguish it from the wbk manB(O-Ag). The fourth gene (provisionally designated wa**) coded for a putative glycosyltransferase involved in inner core synthesis, but the mutant kept the outer core epitope. Differences in phage and polymyxin sensitivity, exposure or expression of outer membrane protein, core and lipid A epitopes, and lipid A acylation demonstrated that small changes in LPS core caused significant differences in B. abortus outer membrane topology. In mice, the mutants showed different degrees of attenuation and induced antibodies to rough LPS and outer membrane proteins. Core-defective mutants and strain RB51 were ineffective vaccines against B. abortus in mice. The mutants per and wbkA induced protection but less than the standard smooth vaccine S19, and controls suggested that anti O-polysaccharide antibodies accounted largely for the difference. Whereas no core-defective mutant was effective against B. ovis, S19, RB51, and the wbkA and per mutants afforded similar levels of protection. These results suggest that rough Brucella vaccines should carry a complete core for maximal effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.